摘要
To study on the effect of clinical pathway （CP） on controlling pharmaceutical costs, we selected complex, chronic, non-communicable diseases, including cerebral infarction, cerebral hemorrhage, transient ischemic attack, and chronic obstructive pulmonary disease, as diseases to implement clinical pathways at a tertiary hospital in Qingdao. We then conducted intermittent time series analysis on pharmaceutical costs. After the implementation of clinical pathway, overall pharmaceutical costs of patients with transient ischemic attack reduced significantly. The effect was not significant for cerebral hemorrhage patients. The implementation of clinical pathway has a desirable outcome on controlling pharmaceutical costs.
为了探索临床路径在有效控制用药费用中的作用,我们选取青岛某三级医院复杂的慢性非传染性疾病:脑梗死、脑出血、短暂性脑缺血发作及慢性阻塞性肺疾病作为路径实施病种,对其药费进行间断时间序列分析。在实施临床路径后总体用药费用、短暂性脑缺血发作患者用药费用显著降低,对脑出血患者的降低用药费用效果不明显。综上所述,实施临床路径对促进用药费用降低有一定作用。
